All In Biotech

Investigational drug · Phase 2

RYZ711

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "RYZ711"

First trial start

2026

Oct 5, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RYZ711", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Prostate Cancer (Adenocarcinoma)
  • Adenocarcinoma of the Prostate
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Biochemical Recurrence (BCR)
  • High-Risk Localized Prostate Cancer

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "RYZ711" as an intervention, largest first.

All trials
  • RayzeBio, Inc.Industry

    NCT07862582 · 116 participants (planned) · Start Oct 5, 2026 · Primary completion Dec 2027

    Drug: RYZ711 · For: Prostate Cancer (Adenocarcinoma); Adenocarcinoma of the Prostate; Metastatic Castration-resistant Prostate Cancer (mCRPC) and 3 more

    Sites: Omaha, Nebraska

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Prostate Cancer (Adenocarcinoma)

  • aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials

    Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)

  • AS1986NSPhase 21 trial

    Antelope Surgical Solutions, Inc · Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.